secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elevation Oncology, Inc. (—)
CIK:        0001783032
Form:       8-K
Filed at:   2023-09-22T23:59:59+00:00
Accession:  0001558370-23-015947
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Elevation Oncology receives Nasdaq bid-price deficiency notice; director resigns
--------------------------------------------------------------------------------

- Nasdaq notified on Sep 19, 2023 that bid price below $1.00 for 30 consecutive days; company has until Mar 18, 2024 to regain compliance.
- To cure, closing bid must be at least $1.00 for 10 consecutive business days by Mar 18, 2024.
- Director Colin Walsh resigned effective Sep 21, 2023 citing other professional opportunities; no disagreement with company.
- Steven A. Elms appointed to fill Audit Committee vacancy left by Walsh's resignation.
- Company considering actions to regain compliance; no assurance of success or continued listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783032/000155837023015947/0001558370-23-015947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783032/000155837023015947/elev-20230919x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-015947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer